Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lilly Says CMS Review Of Beta-Amyloid PET Goes Beyond Medicare Statutory Criteria

This article was originally published in The Pink Sheet Daily

Executive Summary

“Improvement in health outcomes” standard would interpret “the statute to require both diagnosis and treatment,” Lilly says about CMS’ recent evaluation of beta-amyloid positron emission tomography in dementia and neurodegenerative disease.


Related Content

CMS Sticks To Its Guns: Amyvid Alzheimer’s Screening Not Covered In Medicare Population
Imaging Groups Disappointed By CMS’ Final Beta Amyloid PET NCD
CMS’ Amyvid Final NCD Clarifies Trial Outcomes Goals
Imaging Groups Oppose CMS Coverage Proposal For Beta-Amyloid PET
Special Protocol Assessment For Navidea’s Parkinson’s Diagnostic Could Help With Coverage
Alzheimer’s Community Prepares To Challenge CMS Amyvid Proposal
Medicare Coverage Decision For Amyvid Due July 2013
Alzheimer’s Research To Be More Collaborative, Better Funded Under National Plan
Medicare Part B Drug "Least Costly Alternative" Policy Rescinded By CMS


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts